Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 247

1.

Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products.

Raynaud FI, Boxall FE, Goddard P, Barnard CF, Murrer BA, Kelland LR.

Anticancer Res. 1996 Jul-Aug;16(4A):1857-62.

PMID:
8712713
2.

Biotransformation of the platinum drug JM216 following oral administration to cancer patients.

Raynaud FI, Mistry P, Donaghue A, Poon GK, Kelland LR, Barnard CF, Murrer BA, Harrap KR.

Cancer Chemother Pharmacol. 1996;38(2):155-62.

PMID:
8616906
3.
4.

Metabolic studies of an orally active platinum anticancer drug by liquid chromatography-electrospray ionization mass spectrometry.

Poon GK, Raynaud FI, Mistry P, Odell DE, Kelland LR, Harrap KR, Barnard CF, Murrer BA.

J Chromatogr A. 1995 Sep 29;712(1):61-6.

PMID:
8556156
5.

Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.

Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR.

Cancer Res. 1993 Jun 1;53(11):2581-6.

6.

cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.

Raynaud FI, Boxall FE, Goddard PM, Valenti M, Jones M, Murrer BA, Abrams M, Kelland LR.

Clin Cancer Res. 1997 Nov;3(11):2063-74.

7.

Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.

McKeage MJ, Kelland LR, Boxall FE, Valenti MR, Jones M, Goddard PM, Gwynne J, Harrap KR.

Cancer Res. 1994 Aug 1;54(15):4118-22.

8.

Determination of metabolites of a novel platinum anticancer drug JM216 in human plasma ultrafiltrates.

Poon GK, Mistry P, Raynaud FI, Harrap KR, Murrer BA, Barnard CF.

J Pharm Biomed Anal. 1995 Nov;13(12):1493-8.

PMID:
8788134
12.

Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days.

Sessa C, Minoia C, Ronchi A, Zucchetti M, Bauer J, Borner M, de Jong J, Pagani O, Renard J, Weil C, D'Incalci M.

Ann Oncol. 1998 Dec;9(12):1315-22.

13.

Tetravalent platinum complexes with ammine/amine carrier ligand configuration: circumvention of platinum resistance in vivo.

Siddik ZH, Thai G, Yoshida M, Zhang YP, Khokhar AR.

Anticancer Drug Des. 1994 Dec;9(6):495-509.

PMID:
7880375
14.

The tissue distribution in BALB/c mice of C-14-labeled JM216, an orally active platinum antitumour compound.

Bates PI, Sharma HL, Murrer BA, McAuliffe CA.

Cancer Chemother Pharmacol. 1996;39(1-2):170-5.

PMID:
8995517
15.
16.

Binding properties of an orally active platinum anti-tumor drug JM216 with metallothionein in vivo.

Xing B, Zhu H, Wang Y, Tang W.

Biometals. 2000 Sep;13(3):203-8.

PMID:
11127891
17.

Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.

Goddard PM, Orr RM, Valenti MR, Barnard CF, Murrer BA, Kelland LR, Harrap KR.

Anticancer Res. 1996 Jan-Feb;16(1):33-8.

PMID:
8615631
18.

Rapid biotransformation of satraplatin by human red blood cells in vitro.

Carr JL, Tingle MD, McKeage MJ.

Cancer Chemother Pharmacol. 2002 Jul;50(1):9-15. Epub 2002 May 22.

PMID:
12111106
19.

Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.

Vouillamoz-Lorenz S, Buclin T, Lejeune F, Bauer J, Leyvraz S, Decosterd LA.

Anticancer Res. 2003 May-Jun;23(3C):2757-65.

PMID:
12926110
20.

Kinetics of tissue disposition of cis-ammine/cyclohexylamine-dichloroplatinum(II) and cisplatin in mice bearing FSaIIC tumors.

Yoshida M, Khokhar AR, Zhang YP, Thai G, Siddik ZH.

Cancer Chemother Pharmacol. 1994;35(1):38-44.

PMID:
7987975
Items per page

Supplemental Content

Write to the Help Desk